Related Experiment Video

Updated: Jun 22, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma

Joseph Schwab1, Cristina Antonescu, Patrick Boland

  • 1Department of Orthopedic Surgery, Section of Orthopedic Oncology, Sarcoma Research Laboratory, Massachusetts General Hospital, Boston, MA 02114, U.S.A. jhschwab@partners.org

Anticancer Research
|June 17, 2009
PubMed
Abstract

Insights

The PI3K/mTOR pathway is active in chordoma tumors. Inhibiting this pathway with PI-103 drug significantly reduces tumor cell proliferation and increases cell death, offering a potential new treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chordomas are rare bone tumors of the axial skeleton.
  • Surgical resection is the primary curative treatment for chordomas.
  • The PI3K/AKT and mTOR signaling pathway is a key regulator of cell growth and survival.

Purpose of the Study:

  • To investigate the activation status of the PI3K/mTOR pathway in chordomas.
  • To evaluate the therapeutic potential of inhibiting this pathway in chordoma cells.

Main Methods:

  • Analysis of PI3K/mTOR pathway activation in thirteen human chordoma specimens.
  • Treatment of the human chordoma cell line UCH-1 with PI-103, a PI3K/AKT and mTOR inhibitor.
  • Assessment of AKT and mTOR inhibition, cell proliferation, and apoptosis following PI-103 treatment.

Main Results:

  • Chordoma specimens confirmed activation of the PI3K/mTOR pathway.
  • PI-103 effectively inhibited AKT and mTOR activation in the UCH-1 cell line.
  • PI-103 treatment led to decreased proliferation and induced apoptosis in UCH-1 cells.

Conclusions:

  • The PI3K/AKT and mTOR signaling pathway is constitutively active in chordoma.
  • Inhibition of the PI3K/mTOR pathway with PI-103 demonstrates anti-proliferative and pro-apoptotic effects in chordoma cells.
  • Targeting the PI3K/mTOR pathway represents a promising therapeutic strategy for chordoma treatment.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...